Neurotez Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Crowdfunding
- Financing Rounds
-
8
Neurotez General Information
Description
Operator of a biopharmaceutical company intended to serve Alzheimer's patients characterized by hyperleptinemia. The company offers screening, identification and characterization of treatments using biochemical, molecular and cell biology in vivo models, enabling medical practitioners to improve the lives of their patients and serve the public responsibly.
Contact Information
Website
www.neurotez.comCorporate Office
- 991 Highway 22
- Suite 200A
- Bridgewater, NJ 08807
- United States
Corporate Office
- 991 Highway 22
- Suite 200A
- Bridgewater, NJ 08807
- United States
Neurotez Timeline
Neurotez Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Neurotez Comparisons
Industry
Financing
Details
Neurotez Competitors (12)
One of Neurotez’s 12 competitors is Cerecin, a Venture Capital-Backed company based in Singapore, Singapore.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Cerecin | Venture Capital-Backed | Singapore, Singapore | ||||
Cellix Bio | Venture Capital-Backed | Newark, NJ | ||||
Ability Pharma | Private Equity-Backed | Barcelona, Spain | ||||
Centrexion Therapeutics | Venture Capital-Backed | Boston, MA | ||||
Bristol-Myers Squibb | Corporation | Princeton, NJ |
Neurotez Patents
Neurotez Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20140088000-A1 | Leptin rescues neurons from alzheimer's disease related pathways triggered by lipid burden | Inactive | 27-Sep-2012 | ||
US-20130065825-A1 | Compositions and methods for delaying senescence or cell death in neurons | Inactive | 14-Sep-2011 | ||
US-20120231457-A1 | Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load) | Inactive | 10-Mar-2011 | ||
AU-2009313562-A1 | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta | Active | 04-Nov-2008 | ||
AU-2009313562-B2 | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta | Inactive | 04-Nov-2008 | A61K38/22 |
Neurotez Signals
Neurotez Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Neurotez FAQs
-
When was Neurotez founded?
Neurotez was founded in 2005.
-
Where is Neurotez headquartered?
Neurotez is headquartered in Bridgewater, NJ.
-
What is the size of Neurotez?
Neurotez has 7 total employees.
-
What industry is Neurotez in?
Neurotez’s primary industry is Drug Discovery.
-
Is Neurotez a private or public company?
Neurotez is a Private company.
-
What is Neurotez’s current revenue?
The current revenue for Neurotez is
. -
How much funding has Neurotez raised over time?
Neurotez has raised $150M.
-
Who are Neurotez’s investors?
CRG Capital Partners, U.S. Department of Health and Human Services, and National Institutes of Health have invested in Neurotez.
-
Who are Neurotez’s competitors?
Cerecin, Cellix Bio, Ability Pharma, Centrexion Therapeutics, and Bristol-Myers Squibb are some of the 12 competitors of Neurotez.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »